Special Issue

Advances in Targeted Therapy for Hematological Malignancies

Message from the Guest Editor

Advances in targeted therapy for hematological malignancies have revolutionized treatment, providing new hope for patients with blood cancers. These therapies specifically target molecular and genetic abnormalities in cancer cells, minimizing damage to normal cells and reducing side effects compared to traditional chemotherapies. Tyrosine kinase inhibitors (TKIs) have transformed chronic myeloid leukemia (CML) treatment, and chemo-free regimens are under investigation for B-cell precursor acute lymphoid leukemia. Bruton's tyrosine kinase (BTK) inhibitors are effective in different B-cell, indolent, non-Hodgkin lymphomas. Monoclonal antibodies targeting CD20 on B-cells and CD38 on plasma cells, are now essential in treating B-cell lymphomas and multiple myeloma. Additionally, bispecific T-cell engagers (BiTEs) and chimeric antigen receptor (CAR) T-cell therapies have shown remarkable success in refractory and relapsed acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL). These innovations highlight a shift towards personalized medicine in hematology, aiming to enhance the efficacy and scope of targeted therapies.

Guest Editor

Dr. Andrea Visentin

Department of Medicine-DIMED, Hematology Unit, University of Padova, 35128 Padova, Italy

Deadline for manuscript submissions

closed (31 March 2025)

Targets

an Open Access Journal by MDPI

mdpi.com/si/207625

Targets
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
targets@mdpi.com

mdpi.com/journal/targets

Targets

an Open Access Journal by MDPI

mdpi.com/journal/targets

About the Journal

Message from the Editor-in-Chief

Targets is an Open access journal devoted to the fast publication of the latest achievements in bio-detection and therapy. It provides important supports for the development of the related interdisciplinary areas of chemistry, life science, biomedicine, material science, and environment science, particularly in new drug development, disease diagnosis, early warning and targeted therapy, life process study, food and environment safety monitoring, quality control of products, forensic medicine, and even anti-terrorism.

Editor-in-Chief

Prof. Dr. Huangxian Ju
State Key Laboratory of Analytical Chemistry for Life Science, School of Chemistry and Chemical Engineering, Nanjing University, Nanjing 210023, China

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

Rapid Publication:

first decisions in 18 days; acceptance to publication in 4 days (median values for MDPI journals in the second half of 2024).

Recognition of Reviewers:

APC discount vouchers, optional signed peer review, and reviewer names published annually in the journal.

MDPI